R21

BIOLOGICAL4 trials

Sponsors

University of Oxford, Serum Institute of India Pvt. Ltd.

Conditions

MalariaMalaria,FalciparumPrevention of Malaria Transmission and Clinical Malaria

Phase 1

A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1

CompletedNCT02572388

University of OxfordMalaria

Start: 2015-10-15End: 2017-08-29Updated: 2019-11-12

Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults

CompletedNCT06507605

Serum Institute of India Pvt. Ltd.Prevention of Malaria Transmission and Clinical Malaria

Start: 2024-08-30End: 2026-01-24Updated: 2026-02-10

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

RecruitingNCT06958198

University of OxfordMalaria,Falciparum

Start: 2025-09-15End: 2026-10-01Target: 56Updated: 2026-03-11

Phase 2

A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M

Active, not recruitingNCT07183371

University of OxfordMalaria,Falciparum

Start: 2025-12-15End: 2026-12-01Target: 360Updated: 2026-03-11

Related Papers

Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

2025-01-104 citations